Evaluation of Piperine's Effects on Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients

Evaluation of the Effects of Piperine on Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20240814062752N1

Enrollment

100

Registered

2025-12-26

Start date

2026-01-10

Completion date

Unknown

Last updated

2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chemotherapy-Induced Peripheral Neuropathy in Breast Cancer Patients. Drug-induced polyneuropathy

Interventions

Intervention 1: Intervention group: Patients in the intervention group will receive one capsule containing 20 mg of piperine daily. This intervention will last for 120 days. The piperine is extracted

Eligibility

Sex/Gender

Female

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Diagnosed with breast cancer by an oncology specialist and preparation for the initiation of chemotherapy Age between 18 and 60 years Written informed consent obtained from the patient to participate in the study No prior use of supplements containing piperine or similar substances Ability to orally ingest the medication No history of allergy to pepper or related products.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Severity of Peripheral Neuropathy:Measurement: Using Nerve Conduction Study (NCS) to assess the extent of peripheral nerve damage.Timeline: Evaluations at baseline and after 120 days of treatment.Criterion: Changes in nerve conduction velocity or neuropathy severity compared to baseline. Timepoint: Baseline (before starting treatment).Day 120 (end of treatment). Method of measurement: Method: Assessed using Nerve Conduction Study (NCS). Details: Measurement of electrical conduction in peripheral nerves (velocity and amplitude of potentials).Standard electrodes will be used, and patients will be evaluated at rest.Results will be compared to baseline values and standard reference data.	—

Measure

Time frame

Severity of Peripheral Neuropathy:Measurement: Using Nerve Conduction Study (NCS) to assess the extent of peripheral nerve damage.Timeline: Evaluations at baseline and after 120 days of treatment.Criterion: Changes in nerve conduction velocity or neuropathy severity compared to baseline. Timepoint: Baseline (before starting treatment).Day 120 (end of treatment). Method of measurement: Method: Assessed using Nerve Conduction Study (NCS). Details: Measurement of electrical conduction in peripheral nerves (velocity and amplitude of potentials).Standard electrodes will be used, and patients will be evaluated at rest.Results will be compared to baseline values and standard reference data.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAmirhosein Khodadadi

Mashhad University of Medical Sciences

Amirhoseinkhodadaddi@gmail.com+98 51 3371 3913

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 7, 2026